Exhibit 99.1

 

 

 

 

 

 

Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update

 

New Chief Technology Officer (CTO) appointed to accelerate innovation and further strengthen organizational capabilities

 

Continuing robust progress in advancing the MosaiQ transfusion diagnostics menu

 

Actively preparing for commercialization of MosaiQ products through planned evaluation placements in Europe

 

Exploring potential partnerships across a broad range of applications for the multimodal and multiplexing MosaiQ by Quotient system

 

Continued strong Alba by Quotient revenues with high single digit growth in Q4 FY21,
exceeded full-year guidance

 

Further strengthened cash position through private placement of Convertible Senior Notes

 

JERSEY, Channel Islands, June 1, 2021

(GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its fourth quarter fiscal 2021 key achievements and summarized recent business developments.

Chief Technology Officer (CTO) - The Company has recruited Dr. Michael Hausmann, currently Senior Director Global R&D, Clinical Diagnostics Division, Thermo Fisher Scientific, to join Quotient as CTO in Q2 FY2022. Dr. Hausmann brings 24 years of experience in the in vitro diagnostics industry. He has extensive experience in R&D from leading multi-site technology and clinical applications and development programs at companies such as Abbott, bioMérieux and most recently, Thermo Fisher Scientific. As a new member of the executive leadership team, Dr. Hausmann will bring his expertise to advance Quotient’s technology transfer, assay development and commercial launch activities.

“We are delighted to welcome Michael to the Quotient team as our new CTO, a role to which he is perfectly suited. I’ve known Michael for a number of years, and I have seen the extent of his professional contributions and have followed his executive career progression. I’m confident that he’s the right person to further accelerate our innovation development strategy and take our team to the next level,” said Manuel O. Méndez, Chief Executive Officer of Quotient.

“Turning technology into clinical solutions that create medical and operational efficiency value for patients and customers, is a great passion of mine. I look forward to working with the teams in Edinburgh and Eysins and connecting with partners and customers. I am thrilled to join the Quotient organization and look forward to expanding the transfusion diagnostics offering, and accelerating market introductions of the multimodal, multiplexing MosaiQ technology, in immunohematology and beyond,” said Dr. Hausmann.

Michael holds a Ph.D. in Biology from the Max-Planck-Institute of Immunobiology and a MSc degree in Chemistry from Albert-Ludwigs-University in Freiburg, Germany.

 


The following information was filed by Quotient Ltd (QTNT) on Tuesday, June 1, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Quotient Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Quotient Ltd.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account